Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 4/20 | 1.00 |
| ▸ | SKP2 | Q13309 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.85 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.85 |
| ▸ | MEN1 | O00255 | 5/20 | 0.85 |
| ▸ | LMNA | P02545 | 2/20 | 0.85 |
| ▸ | MAPT | P10636 | 2/20 | 0.85 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.85 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.85 |
| ▸ | TP53 | P04637 | 1/20 | 0.85 |
| ▸ | HPGD | P15428 | 1/20 | 0.85 |
| ▸ | TSHR | P16473 | 1/20 | 0.85 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.85 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.85 |
| ▸ | SLC40A1 | Q9NP59 | 10/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.67 |
| ▸ | NFKBIA | P25963 | 3/20 | 0.62 |
| ▸ | RELA | Q04206 | 2/20 | 0.62 |
| ▸ | MITF | O75030 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29575795 | 0.92 | KMT2A (1.00) | CKS1BSKP2KMT2ATDP1MEN1 | |
| SCHEMBL1505430 | 0.92 | KMT2A (1.00) | CKS1BSKP2KMT2ATDP1MEN1 | |
| SCHEMBL17538432 | 0.92 | CKS1B (0.84) | CKS1BSKP2KMT2ATDP1MEN1 | |
| SCHEMBL13633886 | 0.90 | MEN1 (1.00) | CKS1BSKP2KMT2ATDP1MEN1 | |
| SCHEMBL17506534 | 0.87 | CKS1B (1.00) | CKS1BSKP2KMT2ATDP1MEN1 | |
| SCHEMBL17506539 | 0.84 | KMT2A (0.79) | CKS1BSKP2KMT2ATDP1MEN1 | |
| SCHEMBL7197593 | 0.83 | SLC40A1 (1.00) | CKS1BSKP2KMT2ATDP1MEN1 | |
| SCHEMBL17570175 | 0.83 | SLC40A1 (0.78) | CKS1BSKP2KMT2ATDP1MEN1 | |
| SCHEMBL22111633 | 0.82 | MEN1 (0.84) | CKS1BSKP2KMT2ATDP1MEN1 | |
| SCHEMBL4489851 | 0.82 | MEN1 (0.84) | CKS1BSKP2KMT2ATDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3180328-B1 | QUINOLINE DERIVATIVES USEFUL AS UBIQUITINATION INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2020-03-18 | — | — | EP | claimed |
| EP-3180328-A1 | QUINOLINE DERIVATIVES USEFUL AS UBIQUITINATION INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2017-06-21 | — | — | EP | claimed |
| WO-2016025779-A1 | QUINOLINE DERIVATIVES USEFUL AS UBIQUITINATION INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-18 | — | — | WO | claimed |
| EP-3180328-B1 | QUINOLINE DERIVATIVES USEFUL AS UBIQUITINATION INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| EP-3180328-B1 | QUINOLINE DERIVATIVES USEFUL AS UBIQUITINATION INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-10040766-B2 | Ubiquitination inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10040766-B2 | Ubiquitination inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10040766-B2 | Ubiquitination inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| EP-3180328-A1 | QUINOLINE DERIVATIVES USEFUL AS UBIQUITINATION INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20160068490-A1 | UBIQUITINATION INHIBITORS | MIDCAP FINANCIAL TRUST | 2016-03-10 | — | — | US | disclosed |
| US-20160068490-A1 | UBIQUITINATION INHIBITORS | MIDCAP FINANCIAL TRUST | 2016-03-10 | — | — | US | disclosed |
| US-20160068490-A1 | UBIQUITINATION INHIBITORS | MIDCAP FINANCIAL TRUST | 2016-03-10 | — | — | US | disclosed |
| WO-2016025779-A1 | QUINOLINE DERIVATIVES USEFUL AS UBIQUITINATION INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068490-A1 | UBIQUITINATION INHIBITORS | MDM2, RBX1, NEDD4 | CKS1B 206/4885SKP2 51/4885KMT2A 501/4885 |
| US-10040766-B2 | Ubiquitination inhibitors | MDM2, RBX1, NEDD4 | CKS1B 206/4885SKP2 51/4885KMT2A 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.